![]() ![]() In addition, it is believed that an estimated one-third of the global population is Mtb infected. According to the World Health Organization, there were 1.8 million deaths and 10.4 million clinical TB patients globally in 2015. Tuberculosis (TB) caused mainly by Mtb remains one of the leading cause of death due to an infectious agent. Therefore, any institution or individual that is interested in accessing such data must make a formal request and agreement with the Norwegian Center for Research data.įunding: This work was supported by The Research Council of Norway (GLOBVAC PROJECT: 196397/S50).Ĭompeting interests: The authors have declared that no competing interests exist. ![]() The purpose of storing data with this center is for data protection (personal information). This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Data are available from the Norwegian Center for Research data ( after competition of research projects. Received: SeptemAccepted: DecemPublished: January 26, 2018Ĭopyright: © 2018 Abebe et al. ![]() PLoS ONE 13(1):Įditor: Olivier Neyrolles, Institut de Pharmacologie et de Biologie Structurale, FRANCE F, Ottenhoff THM (2018) IgA and IgG against Mycobacterium tuberculosis Rv2031 discriminate between pulmonary tuberculosis patients, Mycobacterium tuberculosis-infected and non-infected individuals. In addition, the current and previous studies consistently show that IgA and IgG against Rv2031 discriminate between clinical disease, Mtb-infected and non-infected individuals.Ĭitation: Abebe F, Belay M, Legesse M, K. Our results show that there are significant variations in IgA, IgG and IgM responses to the different antigens and in the three cohorts, implying that not all antibody isotype responses are markers of clinical TB. Similarly, there were also significant variations in antibody responses in HHCs over time. IgM against HBHA did not show any significant variation before and after chemotherapy. However, the levels of IgM against Rv2031 and LAM increased at 6 months but decreased again at 12 months. The levels of IgA and IgG against HBHA, and IgA against Rv2031 decreased significantly and remained low, while IgA and IgG against LAM increased significantly and remained high following chemotherapy. In patients, there was a significant variation in antibody responses before and after chemotherapy. At baseline, the level of IgM against RV2031 and LAM did not vary between cohorts, but the levels of IgA and IgG against Rv2031 were significantly higher in PTB patients than HHCs and CCs, followed by HHCs, and the lowest in CCs. The results show that there were significant differences in IgA, IgG, and IgM responses to the different antigens and in the three cohorts. ELISA was used to measure levels of IgA, IgG, and IgM from sera of cohorts at baseline, and at 6 and 12 months from entry. As part of a major project to investigate protective and diagnostic immune markers against tuberculosis (TB), we measured antibody isotype responses to Mycobacterium tuberculosis ( Mtb) antigens (LAM, Rv2031, and HBHA) in cohorts of 149 pulmonary tuberculosis patients (PTBP), 148 household contacts (HHCs), and 68 community controls (CCs) in an endemic setting. ![]()
0 Comments
Leave a Reply. |